A new set of 5-chlorobenzoxazole- and 5-chlorobenzothiazole-based derivatives containing the azepane ring as a basic moiety was designed, synthesized and evaluated through binding assays to measure their affinity and selectivity towards σ 1 and σ 2 receptors. Compounds 19, 22 and 24, with a four units spacer between the bicyclic scaffold and the azepane ring, showed nanomolar affinity towards both receptor subtype and the best K i values (K i σ 1 = 1.27, 2.30, and 0.78 and K i σ 2 = 7.9, 3.8, and 7.61 nM, respectively). Evaluation of cytotoxic and apoptotic effects in MCF-7 human cancer cells was useful to assess σ 2 receptor activity, while an in vivo mice model of inflammatory pain allowed to analyze σ 1 receptor pharmacological properties. In vitro and in vivo results suggested that compound 19 is a σ 1 /σ 2 agonist, compound 24 a σ 1 antagonist/σ 2 agonist, whereas compound 22 might act as σ 1 antagonist/σ 2 partial agonist. Due to their pharmacological profile, a potential therapeutic application in cancer of aforesaid novel σ 1 /σ 2 receptor ligands, especially 22 and 24, is proposed.

Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands

Romeo, Giuseppe;Prezzavento, Orazio;Intagliata, Sebastiano;Pittalà, Valeria;Modica, Maria N.;Marrazzo, Agostino;Turnaturi, Rita;Parenti, Carmela;Chiechio, Santina;Arena, Emanuela;Campisi, Agatina;Sposito, Giovanni;Salerno, Loredana
2019

Abstract

A new set of 5-chlorobenzoxazole- and 5-chlorobenzothiazole-based derivatives containing the azepane ring as a basic moiety was designed, synthesized and evaluated through binding assays to measure their affinity and selectivity towards σ 1 and σ 2 receptors. Compounds 19, 22 and 24, with a four units spacer between the bicyclic scaffold and the azepane ring, showed nanomolar affinity towards both receptor subtype and the best K i values (K i σ 1 = 1.27, 2.30, and 0.78 and K i σ 2 = 7.9, 3.8, and 7.61 nM, respectively). Evaluation of cytotoxic and apoptotic effects in MCF-7 human cancer cells was useful to assess σ 2 receptor activity, while an in vivo mice model of inflammatory pain allowed to analyze σ 1 receptor pharmacological properties. In vitro and in vivo results suggested that compound 19 is a σ 1 /σ 2 agonist, compound 24 a σ 1 antagonist/σ 2 agonist, whereas compound 22 might act as σ 1 antagonist/σ 2 partial agonist. Due to their pharmacological profile, a potential therapeutic application in cancer of aforesaid novel σ 1 /σ 2 receptor ligands, especially 22 and 24, is proposed.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/364921
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 21
social impact